Sun Pharmaceutical Industries Ltd. closed 14.89% short of its 52-week high of 1,960.20 rupees, which the company achieved on ...

After falling 17 per cent since the start of the year to its March lows, the stock of the country’s largest pharmaceutical ...

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug ...

According to the USFDA, a Class II recall is issued when the use of or exposure to a violative product may cause temporary or ...

Sun Pharmaceutical Industries Ltd. closed 13.91% short of its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

Analysts believe the key question is whether India can be exempted from the pharma tariffs, given the better relationship ...

Discover the Sun Pharma Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Sun Pharma share price has seen a 10% decline in year-to-date (YTD) performance and an 11% drop over the past six months.

Shares of Indian pharmaceutical companies surged on Thursday after the US exempted the sector from new trade tariffs. The ...